2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-[5-[3-(dimethylamino)propoxy]-2-hydroxyphenyl]-, (2E)- manufacturers
|
| | 2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-[5-[3-(dimethylamino)propoxy]-2-hydroxyphenyl]-, (2E)- Basic information |
| | 2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-[5-[3-(dimethylamino)propoxy]-2-hydroxyphenyl]-, (2E)- Chemical Properties |
| Boiling point | 599.0±50.0 °C(Predicted) | | density | 1.265±0.06 g/cm3(Predicted) | | pka | 7.80±0.45(Predicted) |
| | 2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-[5-[3-(dimethylamino)propoxy]-2-hydroxyphenyl]-, (2E)- Usage And Synthesis |
| Uses | Anti-inflammatory agent 17 is a potent and orally active anti-inflammatory agent. Anti-inflammatory agent 17 inhibits the release of IL-6 and TNF-α in vitro experiments without cytotoxicity. Anti-inflammatory agent 17 exhibits anti-inflammatory activity in vivo. Anti-inflammatory agent 17 has the potential for the research of Acute lung injury (ALI)[1]. | | in vivo | Anti-inflammatory agent 17 (20 mg/kg; intragastric administration) exhibits protective effect on LPS (lipopolysaccharide)-induced ALI in mice[1]. | Animal Model: | C57/BL6 mice[1] | | Dosage: | 20 mg/kg | | Administration: | Intragastric administration | | Result: | Exhibited protective effect on LPS-induced ALI in mice. |
| | IC 50 | TNF-α: 2.576 μM (IC50); IL-6: 8.254 μM (IC50) | | References | [1] Wang X,et al. Design, synthesis and bioactivity evaluation of fisetin derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury. Bioorg Med Chem. 2021; 49:116456. DOI:10.1016/j.bmc.2021.116456 |
| | 2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-[5-[3-(dimethylamino)propoxy]-2-hydroxyphenyl]-, (2E)- Preparation Products And Raw materials |
|